MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis

SIMPLE SUMMARY: MET exon 14 splice-site mutations occur in ~3–4% of lung adenocarcinoma cases, defining a cohort of patients which might benefit from anti-MET targeted therapy. Such therapies have yielded mixed results, however, pointing to the need for better treatment design. Our study sought to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Daniel, Nagelberg, Amy, Chow, Justine LM, Chen, Yankuan T, Michalchuk, Quentin, Somwar, Romel, Lockwood, William W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946549/
https://www.ncbi.nlm.nih.gov/pubmed/35326531
http://dx.doi.org/10.3390/cancers14061378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946549/
https://www.ncbi.nlm.nih.gov/pubmed/35326531
http://dx.doi.org/10.3390/cancers14061378

Ejemplares similares